ES2398221T3 - Anticuerpos inhibidores que se unen al complejo del activador del plasminógeno tipo uroquinasa (uPA y su receptor (uPAR) - Google Patents

Anticuerpos inhibidores que se unen al complejo del activador del plasminógeno tipo uroquinasa (uPA y su receptor (uPAR) Download PDF

Info

Publication number
ES2398221T3
ES2398221T3 ES05754219T ES05754219T ES2398221T3 ES 2398221 T3 ES2398221 T3 ES 2398221T3 ES 05754219 T ES05754219 T ES 05754219T ES 05754219 T ES05754219 T ES 05754219T ES 2398221 T3 ES2398221 T3 ES 2398221T3
Authority
ES
Spain
Prior art keywords
upar
cells
antibody
upa
therapeutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05754219T
Other languages
English (en)
Spanish (es)
Inventor
Graham C. Parry
Andrew P. Mazar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactic Pharma LLC
Original Assignee
Attenuon LLC
Tactic Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon LLC, Tactic Pharma LLC filed Critical Attenuon LLC
Application granted granted Critical
Publication of ES2398221T3 publication Critical patent/ES2398221T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
ES05754219T 2004-05-25 2005-05-25 Anticuerpos inhibidores que se unen al complejo del activador del plasminógeno tipo uroquinasa (uPA y su receptor (uPAR) Expired - Lifetime ES2398221T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57389604P 2004-05-25 2004-05-25
US573896P 2004-05-25
PCT/US2005/018322 WO2005116077A2 (en) 2004-05-25 2005-05-25 LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY

Publications (1)

Publication Number Publication Date
ES2398221T3 true ES2398221T3 (es) 2013-03-14

Family

ID=35451457

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05754219T Expired - Lifetime ES2398221T3 (es) 2004-05-25 2005-05-25 Anticuerpos inhibidores que se unen al complejo del activador del plasminógeno tipo uroquinasa (uPA y su receptor (uPAR)

Country Status (16)

Country Link
US (1) US8101726B2 (enExample)
EP (1) EP1765397B1 (enExample)
JP (1) JP4890449B2 (enExample)
KR (1) KR20070047246A (enExample)
CN (1) CN101022830A (enExample)
AU (1) AU2005248400A1 (enExample)
CA (1) CA2568428C (enExample)
DK (1) DK1765397T3 (enExample)
ES (1) ES2398221T3 (enExample)
IL (1) IL179565A0 (enExample)
MX (1) MXPA06013709A (enExample)
PL (1) PL1765397T3 (enExample)
PT (1) PT1765397E (enExample)
RU (1) RU2006145905A (enExample)
WO (1) WO2005116077A2 (enExample)
ZA (1) ZA200610578B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343489B2 (en) * 2006-03-21 2013-01-01 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
CN1919874B (zh) * 2006-09-18 2010-09-08 中国人民解放军军事医学科学院生物工程研究所 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途
DK2117571T3 (en) * 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2352503B1 (en) * 2008-11-06 2017-07-19 University of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
CN102597775A (zh) 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
CN103391787A (zh) 2010-12-22 2013-11-13 意大利癌症研究基金会分子肿瘤学研究所(Ifom) uPAR拮抗剂及其应用
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
US9867923B2 (en) 2011-05-09 2018-01-16 University Of Miami Reducing soluble urokinase receptor in the circulation
AU2012293720A1 (en) 2011-08-05 2014-02-27 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Constitutively active uPAR variants and their use for the generation and isolation of inhibitory antibodies
PT3929207T (pt) * 2013-03-15 2024-10-21 Univ Texas Utilização do péptido fttftvt no tratamento de fibrose
CN105368859B (zh) * 2015-11-25 2019-10-18 王任直 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用
US10959062B1 (en) 2018-04-19 2021-03-23 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
US10681506B1 (en) 2018-04-19 2020-06-09 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
EP3849580A4 (en) 2018-09-10 2022-06-15 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
WO2020069498A1 (en) 2018-09-28 2020-04-02 Jochen Reiser Supar and prediction and treatment of acute kidney injury
JP7774871B2 (ja) * 2019-10-28 2025-11-25 モナシュ ユニバーシティ プラスミンとの結合のための抗体
JP2023532426A (ja) * 2020-06-15 2023-07-28 モノパー セラピューティクス、インコーポレイテッド 重症ＣＯＶＩＤ－１９疾患の治療のためのウロキナーゼプラスミノーゲン活性化因子受容体（ｕＰＡＲ）の正確な放射線免疫治療標的化
IL306074A (en) 2021-03-24 2023-11-01 Alkermes Inc UPAR antibodies and fusion proteins with them
CA3223227A1 (en) * 2021-05-21 2022-11-24 NorthStar Medical Technologies, LLC Urokinase plasminogen activator receptor-targeted radiopharmaceutical
WO2022261398A1 (en) * 2021-06-11 2022-12-15 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting upar and uses thereof
US20250197838A1 (en) * 2022-03-24 2025-06-19 The United States Government As Represented By The Department Of Veterans Affairs Urokinase-type plasminogen activator receptor binding peptides and methods of use
EP4610269A1 (en) 2024-02-29 2025-09-03 3B Pharmaceuticals GmbH Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
WO2025207781A1 (en) 2024-03-26 2025-10-02 Monopar Therapeutics Inc. Antibody radioisotope constructs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532132A (en) * 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
DE10117381A1 (de) * 2001-04-06 2002-10-10 Wilex Biotechnology Gmbh Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke
US20030219837A1 (en) * 2002-03-18 2003-11-27 Cress Anne E. Integrin ligand
DK2117571T3 (en) * 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope

Also Published As

Publication number Publication date
EP1765397A4 (en) 2009-05-13
PL1765397T3 (pl) 2013-04-30
CA2568428C (en) 2020-12-29
MXPA06013709A (es) 2008-01-16
AU2005248400A1 (en) 2005-12-08
JP2008509086A (ja) 2008-03-27
DK1765397T3 (da) 2013-02-04
IL179565A0 (en) 2007-05-15
PT1765397E (pt) 2013-02-04
EP1765397B1 (en) 2012-10-24
RU2006145905A (ru) 2008-06-27
CN101022830A (zh) 2007-08-22
US8101726B2 (en) 2012-01-24
CA2568428A1 (en) 2005-12-08
JP4890449B2 (ja) 2012-03-07
US20090180952A1 (en) 2009-07-16
WO2005116077A3 (en) 2005-12-29
KR20070047246A (ko) 2007-05-04
EP1765397A2 (en) 2007-03-28
ZA200610578B (en) 2009-09-30
WO2005116077A2 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
ES2398221T3 (es) Anticuerpos inhibidores que se unen al complejo del activador del plasminógeno tipo uroquinasa (uPA y su receptor (uPAR)
ES2636451T3 (es) Epítopo del receptor del activador del plasminógeno tipo uroquinasa
ES2932777T3 (es) Sustratos de matriptasa y activador del plasminógeno-u y otros motivos escindibles y métodos de uso de los mismos
ES2289174T3 (es) Anticuerpos contra el antigeno muc-18.
ES2910407T3 (es) Anticuerpos anti-CD71 activables y procedimientos de uso de los mismos
ES2720594T3 (es) Anticuerpos anti-fXI y métodos de uso
ES2832704T3 (es) Moléculas de unión a HER2 y CD3 biespecíficas
ES2387985T3 (es) Anticuerpos quiméricos y humanizados de integrina alfa 5 beta 1 que modulan la angiogénesis
JP2022104941A (ja) ヒト化抗ｃｄ７３抗体
ES2846400T3 (es) Anticuerpos que se unen a un polipéptido PRL-1 o PRL-3 intracelular
ES2446930T3 (es) Inhibidores de la activación del complemento
ES2307824T3 (es) Uso de anticuerpos contra el antigeno muc18.
ES2992753T3 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
ES2561102T3 (es) Agentes de unión a Notch1 y procedimientos de uso de los mismos
ES2701626T3 (es) Anticuerpos anti-CDH3 y sus usos
ES2524015T3 (es) Proteínas de enlazamiento a la metaloproteinasa
CN119119209A (zh) 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
ES2646792T3 (es) Anticuerpos monoclonales contra bucles extracelulares de C5aR
ES2639227T3 (es) Anticuerpos anti S100A7 para el tratamiento y diagnóstico de cáncer
ES2382039T3 (es) Anticuerpos anti-TLR4/MD-2 neutralizantes y métodos de uso de los mismos
ES2913162T3 (es) Anticuerpo anti-Myl9
ES2396672T3 (es) Forma constitutivamente activa del receptor Notch1 o un anticuerpo anti-receptor Notch1 para el tratamiento de cáncer de próstata
ES2881453T3 (es) Procedimiento para la selección de moléculas de unión biológicas
BR112016006665B1 (pt) Polipeptídeo isolado que compreende uma região clivável (cm) que é um substrato de metaloproteinase de matriz, uso terapêutico do mesmo e método para detectar a presença ou ausência de um agente de clivagem e um alvo de interesse em uma amostra